Tripeptides, E.g., Tripeptide Thyroliberin (trh), Melanostatin (mif), Etc. Patents (Class 530/331)
-
Publication number: 20130011419Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.Type: ApplicationFiled: July 5, 2012Publication date: January 10, 2013Applicant: ImmunoGen, INC.Inventors: Ravi V.J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne Charles Widdison
-
Publication number: 20130012430Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.Type: ApplicationFiled: June 27, 2012Publication date: January 10, 2013Applicant: Vertex Pharmaceuticals IncorporatedInventors: Roger D. Tung, Scott L. Harbeson, David D. Deininger, Mark A. Murcko, Govinda R. Bhisetti, Luc J. Farmer
-
Patent number: 8350003Abstract: The present invention relates to peptides comprising amino acids according to Formula I ((X)l(Y)m)n ??(I) wherein l, m and n are integers from 0 to 10; X and Y, which may be the same or different, are an amino acid selected from the group consisting of hydrophobic amino acids and/or cationic amino acids, together with methods for the use of the peptides in the treatment of microbial infections.Type: GrantFiled: June 28, 2011Date of Patent: January 8, 2013Assignee: Novabiotics LimitedInventor: Deborah O'Neil
-
Publication number: 20130005833Abstract: Compounds represented by general Formula I may form photo-responsive hydrogels that can be modulated between a non-viscous liquid state and a hydrogel. Formula I is: where a stereochemical conformation of double bond “a” is cis- or trans-, Ak is an alkylene group; and R represents a series of two or more naturally occurring or synthetic amino acid residues.Type: ApplicationFiled: July 1, 2011Publication date: January 3, 2013Inventor: Yan Zhang
-
Publication number: 20130005945Abstract: Scaffold comprises a polymer defining macropores and comprising hydroxypropylcellulose partially substituted by a substituent comprising a self-crosslinkable group, which is crosslinked through the self-crosslinkable group. The macropores have an average pore size larger than 50 microns and are at least partially interconnected. In one method, bicontinuous emulsion comprising a continuous aqueous phase and a continuous polymer phase is formed. The polymer phase comprises hydroxypropylcellulose partially substituted by a substituent comprising a self-crosslinkable group, and is crosslinked through the self-crosslinkable group to form a polymer defining at least partially interconnected pores. In another method, phase separation is induced in a solution comprising a polymer precursor and water to form a bicontinuous emulsion comprising a continuous polymer phase and a continuous aqueous phase.Type: ApplicationFiled: September 12, 2012Publication date: January 3, 2013Inventors: Zhilian Yue, Feng Wen, Hanry Yu
-
Patent number: 8343927Abstract: The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.Type: GrantFiled: September 13, 2010Date of Patent: January 1, 2013Assignee: Shire LLCInventors: Travis Mickle, Suma Krishnan, James Scott Moncrief, Christopher Lauderback
-
Patent number: 8344082Abstract: The present invention relates to new molecularly imprinted polymers which are suitable for the selective recognition of glutathione GSH and/or of an analog thereof, and in particular which are of use for the treatment of media comprising in particular a mixture of glutathione GSH, and/or of an analog thereof, with GSH adducts.Type: GrantFiled: October 8, 2008Date of Patent: January 1, 2013Assignee: PolyintellInventors: Celine Perollier, Sami Bayoudh
-
Publication number: 20120329987Abstract: Compositions comprising a tripeptide having the sequence XC1C2; wherein X is any amino acid such that XC1C2 is capable of binding a metal in a square planar orientation or square pyramidal orientation or both; and wherein C1 and C2 are the same or different; and wherein C1 and C2 individually are chosen from a cysteine and a cysteine-like nonnatural amino acid, as well as metal-XC1C2 complexes and methods for forming such complexes.Type: ApplicationFiled: August 28, 2012Publication date: December 27, 2012Applicant: University of KansasInventors: Jennifer Ann Stowell Laurence, Anthony Andrew Vartia, Mary Elizabeth Krause
-
Publication number: 20120329716Abstract: The instant invention relates to peptides obtained from the enzymatic hydrolysis of yellow pea seed proteins that are capable of lowering the blood pressure and reducing the effects of kidney disease in a subject b\ inhibiting or reducing the affinity of the enzymes in the renin-angiotensin system for their substrates, specifically renin, to compositions comprising said peptides and to uses thereof.Type: ApplicationFiled: October 28, 2010Publication date: December 27, 2012Inventors: Rotimi Aluko, Jianping Wu, Harold Aukema
-
Publication number: 20120329985Abstract: This present invention discloses a method for preparing a lipolysis-stimulating soy protein hydrolysate, proceeding a hydrolysis reaction, which is a predetermined concentration of soy protein mediated by Flavourzyme in a predetermined hydrolysis conditions, wherein Flavourzyme versus the soy protein is 1:100, and the optimal hydrolysis conditions including reaction pH value 7˜7.5, reaction temperature 40˜50° C. and hydrolysis time 100˜150 minutes. This invention further discloses nine recombinations of isolated peptide sequences from the soy protein hydrolysate including Val-His-Val-Val, Leu-Leu-Leu, Leu-Leu-Ile, Leu-Ile-Leu, Leu-Ile-Ile, Ile-Leu-Leu, Ile-Leu-Ile, Ile-Ile-Leu and Ile-Ile-Ile.Type: ApplicationFiled: December 25, 2011Publication date: December 27, 2012Applicant: TUNGHAI UNIVERSITYInventors: Wen-Dee Chiang, Hao-Chun Kao
-
Publication number: 20120329705Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.Type: ApplicationFiled: June 8, 2012Publication date: December 27, 2012Inventors: Mark S. Smyth, Guy J. Laidig
-
Patent number: 8338364Abstract: Disclosed are peptides which inhibit the enzymatic activity of tyrosinase as well as formulations and methods for their use in the reduction of skin pigmentation, and methods of administering the inhibitory peptides in a topical formulation. Methods of skin treatment are also provided, the methods further including use of a peptide characterized by the amino acid sequence SFLLRN (SEQ ID NO: 1).Type: GrantFiled: August 10, 2011Date of Patent: December 25, 2012Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventor: Basil M. Hantash
-
Publication number: 20120322748Abstract: The present invention provides novel peptides that facilitate the opening of mammalian tight junctions. i.e. tight junction agonists. The present invention also provides methods for the treatment of disease by administering to a subject suffering from the disease a composition comprising a peptide tight junction agonist of the invention in combination with a therapeutically effective amount of an active agent.Type: ApplicationFiled: May 18, 2012Publication date: December 20, 2012Applicant: Alba Therapeutics CorporationInventors: Amir Tamiz, Min Li
-
Publication number: 20120322722Abstract: The present invention pertains generally to the field of therapeutic compounds and more specifically to certain pyruvamide compounds of the formula (X) (for convenience, collectively referred to herein as “PVA compounds”), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.Type: ApplicationFiled: January 21, 2011Publication date: December 20, 2012Applicants: THE UNIVERSITY OF MANCHESTER, ST GEORGE'S HOSPITAL MEDICAL SCHOOLInventors: Clive Robinson, Jihui Zhang, David Ronald Garrod, Trevor Robert Perrior, Gary Karl Newton, Kerry Jenkins, Rebekah Elisabeth Beevers, Meriel Ruth Major, Mark Richard Stewart
-
Publication number: 20120322741Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical compositions containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.Type: ApplicationFiled: February 25, 2011Publication date: December 20, 2012Applicant: PURDUE RESEARCH FOUNDATIONInventors: Philip Stewart Low, Venkatesh Chelvam, Youngsoon Kim
-
Publication number: 20120322715Abstract: The storage stability of a serine hydrolase acting on ester bonds in a formulation without a protease can be improved by incorporating a serine protease inhibitor.Type: ApplicationFiled: January 4, 2011Publication date: December 20, 2012Applicant: NOVOZYMES A/SInventors: Lise Munch Mikkelsen, Tomas Tage Hansen, Esben Peter Friis
-
Patent number: 8334266Abstract: A process for and intermediates in the preparation of canfosfamide and its salts. Some of the intermediates have anticancer activity.Type: GrantFiled: March 23, 2012Date of Patent: December 18, 2012Assignee: Telik, Inc.Inventors: William A. Boulanger, Steven J. Collier, Stephen A. Eastham, Dennis L. Edie, Ronan Y. Guevel, Pedro E. Hernandez Abad, R. Jason Herr, Hans J. Kjaersgaard, Harold Meckler, Robert E. Polomski, Steven R. Schow, Pavel E. Zhichkin
-
Publication number: 20120309938Abstract: The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R1-R7, X1, X2, R, Q, and n are as defined herein.Type: ApplicationFiled: February 3, 2012Publication date: December 6, 2012Applicant: EISAI CO., LTD.Inventors: James J. KOWALCZYK, Galina KUZNETSOV, Shawn SCHILLER, Boris M. SELETSKY, Mark SPYVEE, Hu YANG
-
Publication number: 20120309674Abstract: The invention relates to compounds, in particular MMP inhibitors. The compounds of the invention have formula (1). The invention can be used in particular in the pharmaceutical field. The present invention also relates to labeled compounds of formula (2), and to the use thereof as contrast agents for detecting extracellular matrix metalloproteinases.Type: ApplicationFiled: August 26, 2010Publication date: December 6, 2012Applicant: Commissariat A L'Energie Atomique ET Aux Ene AltInventors: Laurent Devel, Fabrice Beau, Bertrand Czarny, Vincent Dive
-
Publication number: 20120309944Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there altered profile considered particular useful in therapy.Type: ApplicationFiled: January 24, 2011Publication date: December 6, 2012Applicant: Novo Nordisk Health Care AGInventors: Carsten Behrens, Nils Langeland Johansen, Henrik Sune Andersen, Leif Noerskov-Lauritsen, Jens Buchardt
-
Publication number: 20120309692Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.Type: ApplicationFiled: May 16, 2012Publication date: December 6, 2012Inventors: Samuel R. Denmeade, John T. Isaacs, Hans Lilja
-
Publication number: 20120301474Abstract: The present invention provides vaccine compositions comprising OmpA, or antigenic fragments thereof, and related methods of active immunization against A. baumannii infection. The invention also provides antibodies and antigen-binding parts thereof that specifically bind to OmpA, and related methods of passive immunization against A. baumannii infection. The compositions and methods of the invention are useful for preventing or treating A. baumannii infections, including those caused by strains resistant to carbapenems and all other antibiotics except colistin or tigecycline, also referred to as extreme drug resistant (XDR) A. baumannii infections, and those resistant to every FDA approved antibiotic, also referred to as pan-drug resistant (PDR) A. baumannii infections.Type: ApplicationFiled: May 11, 2012Publication date: November 29, 2012Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Brad J. Spellberg, Lin Lin, Ashraf Ibrahim, Guanpingsheng Luo
-
Publication number: 20120301490Abstract: An immunoconjugate in which a phosphate-prodrugged DNA minor groove binding agent of formula (I), where X is a nucleophilically displaceable leaving group, is conjugated to an antibody or an antigen binding fragment of an antibody, and compounds that can be used for making such immunoconjugates, and uses of such immunoconjugates.Type: ApplicationFiled: May 22, 2012Publication date: November 29, 2012Inventors: QIAN ZHANG, SANJEEV GANGWAR, CHIN PAN, DANIEL W. DERWIN
-
Publication number: 20120294885Abstract: The present disclosure provides novel imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof, and methods of making and using such compounds. The present disclosure also provides TLR7 agonists and TLR7/TLR8 dual agonists, probes, tissue-specific molecules, adjuvants, immunogenic compositions, therapeutic compositions, and self-adjuvanting vaccines including the imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof. Derivatives of the imidazoquinoline derived compounds also include dendrimers and dimers of the imidazoquinoline derived compounds, and methods of making and using the dendrimeic and dimeric imidazoquinoline derived compounds. The present disclosure also provides dual TLR2/TLR7 hybrid agonists that include imidazoquinoline derived compounds of the present disclosure.Type: ApplicationFiled: May 18, 2012Publication date: November 22, 2012Applicant: THE UNIVERSITY OF KANSASInventors: Sunil A. David, Nikunj M. Shukla
-
Publication number: 20120295834Abstract: The embodiments provide prodrug compounds of Formulae I-XV. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug compound of Formulae I-XV that provides controlled release of an opioid. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of an opioid from the prodrug so as to attenuate enzymatic cleavage of the prodrug.Type: ApplicationFiled: March 8, 2012Publication date: November 22, 2012Inventors: Thomas E. Jenkins, Craig O. Husfeld
-
Publication number: 20120294843Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, of formula I: X—W wherein X is a caspase-selective structure and W has the structure of —NH—CH(Y)(Z) wherein Y is a structure that can form a reversible covalent bond with a caspase; and Z is selected from a carboxyl moiety or a carboxylic acid mimetic.Type: ApplicationFiled: January 27, 2011Publication date: November 22, 2012Inventors: Craig Thomas, Matthew B. Boxer
-
Publication number: 20120289461Abstract: A protein synthesis promoter that exhibits a protein synthesis-promoting effect includes a whey protein hydrolyzate having a molecular weight distribution that is within a range of 10 kDa or less and has a main peak of 200 Da to 3 kDa, an average peptide length (APL) of 2 to 8, a free amino acid content of 20% or less, a branched-chain amino acid content of 20% or more, and an antigenicity equal to or less than 1/100,000th of that of ?-lactoglobulin.Type: ApplicationFiled: February 10, 2011Publication date: November 15, 2012Applicant: Megmilk Snow Brand Co., Ltd.Inventor: Susumu Miura
-
Patent number: 8309685Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.Type: GrantFiled: July 2, 2009Date of Patent: November 13, 2012Assignee: Celgene Avilomics Research, Inc.Inventors: Russell C. Petter, Juswinder Singh, Arthur F. Kluge, Deqiang Niu, Lixin Qiao, Shomir Ghosh
-
Patent number: 8304392Abstract: A peptide of formula: R1-X1-X2-X3-X4-X5-R2, wherein X1 is T; S2 is L; X3 is K; X4 is T, S, K, R or no amino acid; X5 is V, A, Y, M or no amino acid; R1 represents a primary amine function of the N-terminal amino acid; and R2 represents a hydroxyl function of the C-terminal amino acid, is capable of activating cytochrome C. The peptide can be included in cosmetic and pharmaceutical compositions intended to stimulate the functions of the mitochondria and increase intracellular ATP levels. Such compositions are useful to help protect the skin from external aggression, reduce and treat skin damage caused by UV radiation and combat cutaneous signs of aging.Type: GrantFiled: April 23, 2008Date of Patent: November 6, 2012Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8304385Abstract: The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.Type: GrantFiled: November 14, 2008Date of Patent: November 6, 2012Assignee: Enanta Pharmaceuticals, Inc.Inventors: Ying Sun, Dong Liu, Yat Sun Or, Zhe Wang
-
Publication number: 20120277164Abstract: Compounds based around tetrapeptide, tripeptide and dipeptide moeties and corresponding peptiod moeties. Related methods and pharmaceutical compositions for use in treatment of cancer, inflammatory diseases, and other disorders.Type: ApplicationFiled: October 22, 2010Publication date: November 1, 2012Applicant: Imperial Innovations LimitedInventors: Guido Franzoso, Albert Andrzej Jaxa-Chamiec, Caroline Minli Rachel Low, Simona Maria Monti, Menotti Ruvo, Laura Tornatore, Catherine Jane Tralau-Stewart
-
Patent number: 8299129Abstract: The present invention provides a carrier capable of highly efficiently introducing a compound into cells with low cytotoxicity, which contains peptide lipids represented by the following formula, and a method for introducing a compound into cells using the carrier: wherein R1 is an amino acid or peptide having 1-10 amino acid residues, R2 is a side chain of any amino acid, provided that R2 has a carboxyl group, the carboxyl group may be an ester with a hydrocarbon group having 1-30 carbon atoms, R3 is a hydrocarbon group having 1-30 carbon atoms.Type: GrantFiled: March 1, 2006Date of Patent: October 30, 2012Assignees: Fukuoka Prefectural Government, Kyoto University, Dojindo LaboratoriesInventors: Kenichi Kusumoto, Itaru Hamachi, Kazumi Sasamoto, Tetsuyuki Akao, Munetaka Ishiyama, Takahiro Nagata, Chizu Ikeda, Takeshi Ido, Satoko Yamashita, Rieko Kuroda, Tomoyuki Ishikawa
-
Publication number: 20120269769Abstract: Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.Type: ApplicationFiled: July 3, 2012Publication date: October 25, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Montse LLINAS-BRUNET, Murray BAILEY, Punit BHARDWAJ, Josee BORDELEAU, Pasquale FORGIONE, Elise GHIRO, Vida GORYS, Nathalie GOUDREAU, Sylvie GOULET, Teddy HALMOS, Jean RANCOURT
-
Publication number: 20120270775Abstract: This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:Type: ApplicationFiled: July 3, 2012Publication date: October 25, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Thilo BERKENBUSCH, Carl Alan BUSACCA, Burkhard JAEGER, Richard J. VARSOLONA
-
Publication number: 20120271033Abstract: Disclosed are methods for identifying high affinity adaptor molecules that bind to both a circulating antibody and a target molecule and redirect the specificity of the circulating antibody to the target molecule. Exemplary high affinity adaptor molecules are also provided.Type: ApplicationFiled: October 5, 2010Publication date: October 25, 2012Applicant: OPSONIC THERAPEUTICS INC.Inventors: Albert Collinson, Peter Wagner, Matti Sällberg, Anders Vahlne, Gregor Schürmann, Robert Kamen
-
Publication number: 20120270813Abstract: A process for producing a peptide product having cholecystokinin secretion promoting effect, said process comprising hydrolyzing soybean residues with one or more proteases so that the peptide product having cholecystokinin secretion promoting effect is obtained. Also disclosed is the composition containing the peptide product and the use thereof.Type: ApplicationFiled: October 5, 2011Publication date: October 25, 2012Applicant: Food Industry Research and Development InstituteInventors: Yi-Hong Chen, Yu-Hui Liu, Chu-Chin Chen, Shiao-Cheng Chuang, Hsiang-Ling Lai, Chien-Ti Chang, Ming-Yu Hung, Su-Er Liou, Fu-Ning Chien
-
Publication number: 20120270811Abstract: A series of peptides with divergent confirmations including structures of formula (1A), (1B), (2) and (3) are provided. In the formula, wherein U, G, A, B, R1, R2 and T are as defined in the specification. The divergent peptides disclosed in the present invention are characterized in a mineral binding affinity function.Type: ApplicationFiled: October 21, 2011Publication date: October 25, 2012Applicant: KAOHSIUNG MEDICAL UNIVERSITYInventors: Hui-Ting Chen, Kuang-Chan Hsieh, Je-Ken Chang, Gwo-Jaw Wang, Yin-Chih Fu, Mei-Ling Ho, Cherng-Chyi Tzeng
-
Publication number: 20120270795Abstract: The present invention relates to the field of protein misfolding diseases and thus to diseases which are associated with or induced by abnormal or pathogenic three-dimensional folding of proteins and/or peptides or which are linked to pathogenic conformational changes of proteins and/or peptides, such as Alzheimer's disease. Particularly, the present invention provides novel trimeric pyrazole compounds, which exhibit a therapeutic effectiveness in regard to the aforementioned protein misfolding diseases, and refers to their use for the treatment of such protein misfolding diseases, especially neurodegenerative diseases as well as to medicaments or pharmaceutical compositions comprising these compounds.Type: ApplicationFiled: January 26, 2010Publication date: October 25, 2012Inventors: Thomas Schrader, Katrin Hochdörffer, Julia März-Berberich, Luitgard Nagel-Steger, Gal Bitan, Sharmistha Sinha
-
Publication number: 20120270808Abstract: Embodiments of the invention include methods for selecting in parallel (i.e., synchronously or simultaneously) peptides that target a number of organs, in which each peptide targets distinct tissues or organs. Typically, the methods of the invention provide for peptide selection in a Minimal number of subjects and still provides a selectively binding peptide. In certain aspects, methods of identifying peptides that bind to multiple selected tissues or organs of an organism may comprise the steps of administering a phage display library to a first subject; obtaining a sample of two or more selected tissues; obtaining phage displaying peptides that bind to the samples from the first subject; enriching for peptides by administering phage isolated from the samples of the first subject to a second subject; obtaining a sample of two or more selected tissues from the second subject; and identifying the peptides displayed.Type: ApplicationFiled: April 4, 2012Publication date: October 25, 2012Inventors: Mikhail Kolonin, Wadih Arap, Renata Pasqualini
-
Publication number: 20120269797Abstract: Proteasome inhibitors (PI) are used for inhibiting the maturation of dendritic cells (DZ) and thus in the treatment or the prophylaxis of allergies, asthma, tissue or transplant rejection or autoimmune diseases. The concentration of the proteasome inhibitors lies preferably in the range of 10 nM to 10 ?M, based on the peripheral blood or the cytoplasm.Type: ApplicationFiled: July 15, 2010Publication date: October 25, 2012Inventors: Ulrich Schubert, Elisabeth Zinser, Alexander Steinkasserer
-
Publication number: 20120264696Abstract: Preventing skin aging by targeting multiple causes by a single bullet is of primal scientific and consumer interest.Type: ApplicationFiled: February 18, 2012Publication date: October 18, 2012Applicant: Island Kinetics Inc.Inventors: Shyam K. Gupta, Linda Walker
-
Publication number: 20120252739Abstract: The present invention relates to novel tubulin binding molecules of formula (I) and their use for the treatment of cancer and other diseases.Type: ApplicationFiled: November 12, 2010Publication date: October 4, 2012Applicant: R&D Biopharmaceuticals GmbHInventor: Wolfgang Richter
-
Publication number: 20120251581Abstract: There is provided inter alia a compound of formula (I): for use in treatment of viral infection or as an immunosuppressant.Type: ApplicationFiled: March 29, 2012Publication date: October 4, 2012Inventors: Matthew Alan Gregory, Steven James Moss, Barrie Wilkinson
-
Patent number: 8278111Abstract: Compositions comprising a tripeptide having the sequence XC1C2; wherein X is any amino acid such that XC1C2 is capable of binding a metal in a square planar orientation or square pyramidal orientation or both; and wherein C1 and C2 are the same or different; and wherein C1 and C2 individually are chosen from a cysteine and a cysteine-like nonnatural amino acid, as well as metal-XC1C2 complexes and methods for forming such complexes.Type: GrantFiled: December 30, 2011Date of Patent: October 2, 2012Assignee: University of KansasInventors: Jennifer Ann Stowell Laurence, Anthony Andrew Vartia, Mary Elizabeth Krause
-
Publication number: 20120244174Abstract: The invention is directed to methods of treatment of Alzheimer's disease and other tauopathies, via the administration of antibodies having specificity to abnormal forms of tau protein, the antibodies showing no binding and/or reactivity to a normal tau protein and being administered under conditions and in amounts effective to prevent or treat Alzheimer's disease or other tauopathies. In certain embodiments, the antibodies are selective for soluble truncated tau protein truncated at (i) its C-terminus after the glutamic acid residue Glu391, or (ii) at the aspartic acid residue Asp421, or (iii) at its N-terminus at the aspartic acid residue Asp13, or (iv) a combination of (i)-(iii). Further aspects of the invention are directed to the administration of an immunogen comprising an abnormal tau, preferably a soluble truncated tau.Type: ApplicationFiled: January 31, 2012Publication date: September 27, 2012Inventor: Daniel G. Chain
-
Publication number: 20120244122Abstract: This invention relates to novel compounds that are peptides derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel peptides that are deuterated derivatives of boceprevir. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating HCV infection.Type: ApplicationFiled: May 28, 2010Publication date: September 27, 2012Inventor: Craig E. Masse
-
Publication number: 20120245091Abstract: The present invention relates to a polypeptide derived from a highly conserved region (HCR) I-III of an extracellular region of a CD99 and CD99 family such as CD99L2 and PBDX (or XG), which are a kind of transmembrane protein, or a fused protein thereof. The polypeptide or the fused protein thereof has an activating function of inhibiting the extravasation of white blood cells, or inhibiting the growth and/or metastasis of cancer cells. The present invention also provides a polynucleotide coding the polypeptide, a vector including same, and a transformant transformed by the vector. In addition, the present invention provides a pharmaceutical composition including the polypeptide or the fused protein thereof for preventing or treating inflammatory diseases. Further, the present invention provides a pharmaceutical composition including the polypeptide or the fused protein thereof inhibiting the growth and/or metastasis of cancer cells, i.e., a pharmaceutical composition for preventing or treating cancer.Type: ApplicationFiled: August 24, 2010Publication date: September 27, 2012Applicant: SUPADELIXIR INC.Inventors: Jang-Hee Hahn, Kyoung-Jin Lee, Sun-Hee Lee, Hyun-Mi Ju
-
Patent number: 8273716Abstract: The invention relates to methods of treatment or prophylaxis of physiological and/or pathological conditions with at least one LHRH antagonist, in particular at least one peptidomimetic LHRH antagonist such that the at least one LHRH antagonist is administered in a dose, which does not cause chemical (hormonal) castration.Type: GrantFiled: February 27, 2009Date of Patent: September 25, 2012Assignee: Spectrum Pharmaceuticals, Inc.Inventor: Juergen Engel
-
Publication number: 20120237552Abstract: Neurotrophin binding to its specific receptors Trk A and p75 leads to the activation of multiple signalling cascades, culminating in neuroprotective and regenerative effects, including neuronal survival and neurite outgrowth. Neurotrophic factors have been used for the treatment of several neurodegenerative diseases. However, their use is limited by their inability to cross the blood-brain barrier, their short half life and their side effects. Small molecule neurotrophin mimetics may be beneficial in treating a number of neurodegenerative disorders. The present invention shows the capacity of nerve growth factor agonist molecules of Formulae I-IV, as defined in the specification, to induce differentiation in PC 12 cells, promote survival in RN22 cells and activate Trk A, IkBa and SAPK/JNK phosphorylation to various extents in both cell lines.Type: ApplicationFiled: August 31, 2010Publication date: September 20, 2012Inventors: Beatriz Moreno, Pablo Villoslada, Joaquin Messeguer, Gloria Navarro, Angel Messeguer
-
Publication number: 20120238503Abstract: The present invention relates to human laminin ?2 chain LG3 domain and active peptides promoting cell adhesion, spreading, migration, and neurite outgrowth. More particularly, it was found that when nerve cells are incubated using human laminin ?2 chain LG3 domain and active peptides in the LG3 domain, cell adhesion, spreading, migration, and neurite outgrowth of nerve cells promote and the promotion of cell adhesion, spreading, migration, and neurite outgrowth of nerve cells are integrin-mediated and achieved by the activation of PKC? and FAK phosphorylation. Thus, the present invention can be very useful for researches on cell adhesion, spreading, migration, and neurite outgrowth activities of cells which are focused on nerve cells and mediated by various extracellular matrix proteins including laminin, manufacture of artificial nerve conduits, burns treatment, wounds treatment, and tissue regeneration.Type: ApplicationFiled: March 12, 2012Publication date: September 20, 2012Applicant: SNU R&DB FOUNDATIONInventor: Byung-Moo MIN